Washington, D.C.–President Joe Biden has forged a historic manufacturing collaboration between two of the largest U.S. healthcare and pharmaceutical companies, Merck and Johnson and Johnson, to expand the production of Johnson’s COVID-19 vaccine.
The collaboration will increase manufacture of vaccine drug substance, as well as its fill-finish capacity – two of the biggest bottlenecks facing Johnson and Johnson in the production of its vaccine.
The U.S. Department of Health and Human Services will collaborate with Merck to repurpose some of its existing facilities and manufacturing equipment like agitators, Pharma Clean Room Cranes, etc., for rapid large-scale manufacturing of vaccines and therapeutics for use in public health emergencies including the current pandemic. The facilities will be available to private sector partners working with the federal government on the COVID-19 response or to produce Merck products against COVID-19. Janssen Pharmaceuticals, part of Johnson and Johnson, will be the first federal partner to use repurposed Merck facilities to manufacture COVID-19 vaccine. Merck will use two of its facilities to produce drug substance, formulate and fill vials of Johnson and Johnson’s vaccine.
Consistent with the Administration’s mission to ensure that the United States has sufficient long term sustainable capacity to manufacture vaccines, the Biomedical Advanced Research and Development Authority, part of the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, will leverage the Defense Production Act to provide an initial investment of $105 million in funding for Merck, at the Administration’s request, to convert, upgrade and equip Merck facilities to the standards necessary to safely manufacture the vaccine. The company will address all the necessary qualification and validation activities needed for the facilities to be used for large-scale manufacturing.
To further accelerate production of the Johnson and Johnson vaccine, President Biden also announced he has invoked the Defense Production Act to expedite materials in vaccine production, such as equipment, machinery and supplies like single use bags, and he has directed the Department of Defense to provide daily logistical support to strengthen Johnson and Johnson’s efforts. With the urging and assistance of the administration, Johnson and Johnson also will begin operating its manufacturing facilities 24/7 to maximize production output.
Those efforts will contribute to Johnson and Johnson’s ability to accelerate delivery of their vaccine doses from 100 million doses by the end of June to at or near 100 million doses by the end of May. In the long term, these actions will ultimately double Johnson and Johnson’s U.S. capacity to produce drug substances and increase the U.S. capacity for fill-finish.
